Captor Therapeutics Spolka Akcyjna (WSE:CTX)

Poland flag Poland · Delayed Price · Currency is PLN
77.30
-2.50 (-3.13%)
May 7, 2026, 5:00 PM CET
Market Cap507.00M +176.2%
Revenue (ttm)4.66M -70.6%
Net Income-42.00M
EPS-7.61
Shares Out6.35M
PE Ration/a
Forward PE25.35
Dividendn/a
Ex-Dividend Daten/a
Volume3,854
Average Volume2,442
Open78.00
Previous Close79.80
Day's Range76.50 - 79.50
52-Week Range31.30 - 89.20
Beta0.56
RSI48.39
Earnings DateApr 30, 2026

About WSE:CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 91
Stock Exchange Warsaw Stock Exchange
Ticker Symbol CTX
Full Company Profile

Financial Performance

In 2025, WSE:CTX's revenue was 4.66 million, a decrease of -70.55% compared to the previous year's 15.83 million. Losses were -42.00 million, 9.29% more than in 2024.

Financial Statements